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Abstract
Aim: To undertake a systematic review and meta-analysis of prospective studies to determine the effect of
ginger supplementation on serum C-reactive protein (CRP), lipid profile, and glycaemia.
Method: PubMed-MEDLINE, Web of Science, Cochrane Database, and Google Scholar databases were
searched (up until July 2016) to identify prospective studies evaluating the impact of ginger supplementation
on serum CRP. Random-effects model meta-analysis was used for quantitative data synthesis. Sensitivity
analysis was conducted using the leave-one-out method. Heterogeneity was quantitatively assessed using the
I2 index. Systematic review registration: CRD42016035973.
Results: From a total of 265 entries identified via searches, 9 studies were included in the final selection. The
meta-analysis indicated a significant reduction in serum CRP concentrations following ginger supplementation
[weighted mean difference (WMD)0.84 mg/L (95% CI 1.38 to 0.31, I2 56.3%)]. The WMD for fasting
blood glucose and HbA1c was1.35 mg/dl (95% CI 2.04 to 0.58, I2 12.1%) and 1.01 (95% CI 1.28 to
0.72, I2 9.4%), respectively. Moreover, high-density lipoprotein and triglyceride significantly improved after
ginger administration [1.16 mg/dl (95% CI 0.52 to 1.08, I2 12.3%) and 1.63 mg/dl (95% CI 3.10 to 0.17,
I2 8.1%), respectively]. These findings were robust in sensitivity analyses. Random-effects meta-regression
revealed that changes in serum CRP levels were independent of the dosage of ginger supplementation (slope
0.20; 95% CI 0.95 to 0.55; p0.60).
Conclusions: This meta-analysis suggests that ginger supplementation significantly reduces serum CRP and
improves glycaemia indexes and lipid profile. Randomized control trials with larger sample size and with a
longer-term follow-up period should be considered for future investigations.
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C
hronic inflammation has been associated with a
wide range of diseases including cardiovascular
disease (CVD), diabetes, arthritis, Alzheimer’s
disease, pulmonary diseases, and autoimmune diseases
(1, 2). C-reactive protein (CRP) is a plasma protein that
rises in the systemic response to inflammatory conditions
(3); in addition, there is a link between elevated level of this
protein and major cardiovascular events (4, 5). Interleu-
kin-6 (IL-6) is an important inflammatory cytokine that
induces the hepatic production of CRP. A low-grade
inflammation is a common feature of type 2 diabetes
mellitus (DM2) and also has a role in the pathogenesis of
its secondary complications such as atherothrombosis
(6, 7). Inflammation also modifies insulin sensitivity,
diabetes-related dyslipidaemia, and endothelial function
(6, 8).
The rhizome of ginger (Zingiber officinale Roscoe,
Zingiberaceae) is a widely used spice. For centuries, this
plant plays a significant role in Chinese, Ayurvedic, and
Unani-Tibb herbal medicine to treat cataract, rheumatism,
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nervous diseases, gingivitis, toothache, asthma, stroke,
constipation, and diabetes (6, 9). Ginger contains
active phenolic compounds such as gingerol, paradol,
and shogaol that have antioxidant, anti-cancer, anti-
inflammatory, and anti-atherosclerotic properties (1, 10).
Mechanisms of action include modulation of leuko-
triene (LT) and prostaglandin (PG) synthesis and inhi-
bition of nuclear factor-kB (11). In vitro, the main
components of ginger (gingerols and shogaols) can inhibit
the synthesis of several pro-inflammatory cytokines
including IL-1, tumour necrosis factor (TNF)-a, and
IL-8 as well as PG and LT synthesis enzymes (6, 12).
Mahluji et al. have previously shown that 2 g powdered
ginger reduced plasma insulin, insulin resistance assessed
by homeostatic model assessment (HOMA), serum fast-
ing triglyceride (TG), and low-density lipoprotein (LDL),
in type 2 diabetic patients; however, no significant changes
were seen in blood glucose, total cholesterol, or high-
density lipoprotein (HDL) levels (6). Bordia et al. have
reported that ginger supplementation had no significant
effect on blood glucose and serum lipids (8, 13).
Regarding the effect of ginger supplementation on
CRP, Naderi et al. have reported that the concentration
of inflammatory markers including CRP was reduced in
the group treated with ginger compared with the group
receiving placebo (5); moreover, Karimi et al. reported
that the ginger supplementation caused a reduction of hs-
CRP, IL-10, blood glucose, LDL, and TG, and an increase
in HDL (14). Imani et al. indicated that daily adminis-
tration of 1,000 mg ginger reduces serum fasting glucose
(15). However, a few studies have reported an increase (16)
or a non-significant (15) effect of ginger supplementation
on inflammatory markers. Thus, inconsistent findings
have been reported in this field.
Single studies to date have been limited by sample size,
research design, and subject traits (gender, ethnicity, age,
etc.) and underpowered to achieve a comprehensive and
reliable conclusion. Meta-analysis has the benefit to over-
come this limitation by increasing the sample size. Hence,
the present study aimed to resolve this uncertainty by
systematically reviewing the literature, and meta-analysis
and meta-regression of all trials investigating the effects of
ginger on serum CRP, blood lipids, and glycaemia.
Materials and methods
Literature search strategy
The present study was conducted according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) Guidelines (17, 18). Moreover,
the study protocol was registered with the International
Prospective Register of Systematic Reviews, PROSPERO
(registration no.: CRD42016038155). The primary expo-
sure of interest was ginger administration while the
primary outcome of interest was changes in CRP levels,
lipid profile, and glycaemia subsequent to ginger admin-
istration. We searched multiple databases including
PubMed-MEDLINE, Cochrane Central Register of Con-
trolled Trials (CCTR), Cochrane Database of Systematic
Reviews (CDSR), Web of Science; until July 2016 using a
combination of search terms available in Supplementary
Table 1. This was complemented by a physical search of
the reference list of eligible articles and email correspon-
dences with authors for additional data where relevant.
Selection criteria
We included all randomized control trials (RCTs) evalu-
ating the effect of ginger administration on the outcomes
of interest. Eligible studies had to meet the following
criteria: 1) being a controlled trial with either parallel or
crossover design, and 2) presentation of sufficient infor-
mation on primary outcome at baseline and at the end of
follow-up in each group or providing the net change
values. Exclusion criteria were: 1) non-clinical studies; 2)
observational studies with case-control, cross-sectional or
cohort design; and 3) studies that did not provide mean
(or median) plasma concentrations of our interested
outcomes at baseline and/or at the end of trial. Narrative
reviews, comments, opinion pieces, methodological, edi-
torials, letters, or any other publications lacking primary
data and/or explicit method descriptions were also
excluded. Study selection started with the removal of
duplicates, followed by titles and abstracts screening by
two reviewers. To avoid bias, they were blinded to the
names, qualifications, or the institutional affiliations of
the study authors. The agreement between the reviewers
was excellent (k index: 0.89; pB0.001). Disagreements
were resolved at a meeting between reviewers prior to
selected articles being retrieved (Fig. 1).
Data extraction and management
The full text of studies meeting inclusion criteria was
retrieved and screened to determine eligibility by two
reviewers (MM and PR). Following assessment of meth-
odological quality, the two reviewers extracted data using
a purpose-designed data extraction form and indepen-
dently summarized what they considered to be the most
important results from each study. These summaries were
compared and any differences of opinion were resolved by
discussion and consultation with a third reviewer. Any
further calculations on study data considered necessary
were conducted by the first reviewer and checked by the
second reviewer. Descriptive data extracted included the
first author, reference, country, study design, inclusion
criteria, treatment duration, sample size, study groups, age
(years), female (n,%), and ginger dose.
Quality assessment
A systematic assessment of bias in the included RCTs
was performed using the Cochrane criteria (19). The
items used for the assessment of each study were the
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following: adequacy of random sequence generation,
allocation concealment, blinding of participants, person-
nel and outcome assessment, handling of drop-outs
(incomplete outcome data), selective outcome reporting,
and other potential sources of bias. According to the
recommendations of the Cochrane Handbook, a judgment
of ‘yes’ indicated low risk of bias, while ‘no’ indicated high
risk of bias. Labelling an item as ‘unclear’ indicated an
unclear or unknown risk of bias.
Data synthesis
Based on recommendation within the Cochrane Hand-
book, the mean change from baseline in interested variable
concentrations and standard deviation (SD) for both
intervention and control groups was used to calculate
the effect size (19). In brief, net changes in measurements
(change scores) were calculated as follows: measure at end
of follow-up - measure at baseline (20). Where standard
error of the mean (SEM) was only reported, SD was
estimated using the following formula: SDSEM
square root (n), where n is the number of subjects (20). If
the outcome measures were reported as median and range
(or 95% confidence interval (CI)], mean and standard
SD values were estimated using the method described by
Hozo et al. (21). When the outcome variable was available
only in the graphic form, the software GetData Graph
Digitizer 2.24 (20) was used to digitize and extract
the data. Blood lipid and glucose levels were collated in
mmol/L; a multiplication factor of 0.0259, 0.0113, or
0.0555 was used to convert cholesterol (total cholesterol,
HDL-C, or LDL-C), TGs, and glucose levels, respectively,
from mg/dl to mmol/L as appropriate (20).
A random-effects model (using the DerSimonian
Laird method) and the generic inverse variance method
were used (22). Heterogeneity was quantitatively assessed
using I2 index. I2 values B50% and ]50% corresponded
with the use of fixed-effects and random-effects model,
respectively (20). Effect sizes were expressed as weighed
mean difference (WMD) and 95% CI. In order to
evaluate the influence of each study on the overall effect
size, a sensitivity analysis was conducted using the leave-
one-out method (i.e. removing one study each time and
repeating the analysis) (2325).
Meta-regression
Random-effects meta-regression was performed using
the unrestricted maximum likelihood method to evaluate
the association between calculated WMD and potential
moderator including dose of ginger administration.
Publication bias
Potential publication bias was explored using a visual
inspection of Begg’s funnel plot asymmetry, Begg’s rank
correlation, and Egger’s weighted regression tests (20).
Duval and Tweedie’s ‘trim and fill’ and ‘fail-safe N’
methods were used to adjust the analysis for the effects
of publication bias (26). Meta-analysis was conducted
using comprehensive meta-analysis (CMA) V3 software
(Biostat, NJ) (27).
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Records after duplicates removed: 101
Records screened: 164
Records excluded: 96
Full-text articles assessed: 68
Full-text articles excluded, with reasons:
1.Non-human, genetics, molecular
2.Review, not ginger , not relevant
3.Editorial
4.Not RCT
Studies included in systematic review: 9
Fig. 1. PRISMA flow chart for the studies selection.
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Results
Summary of searches and study selection process
A total of 145 unique citations were identified from
searches, of which 99 records remained after removing
duplicates. After screening via titles and abstracts, 21
articles remained for further evaluation, of which 16 were
excluded for the following reasons: non-human studies,
genetic, or molecular studies (n4); reviews or editorial
articles (n7); and not RCTs (n3), short follow-up
duration (n2) (Fig. 1). Therefore, nine studies were
included in the final meta-analysis.
Risk of bias assessment
There was a lack of information about blinding of
participants; however, all the evaluated studies had a low
risk of bias according to selective outcome reporting.
Details of the quality of bias assessment are shown in
Supplementary Table 2.
Characteristics of the included studies
The characteristics of the included studies are summar-
ized in Table 1. These studies were published between 2008
and 2015 from Iran (eight studies) and the United States
of America (one study). The number of participants
included in these studies ranged from 10 (28) to 88 (29).
The mean age of participants ranged from 23.7 years (30)
to 58 years (31). A range of doses from 1 to 3 g per day was
administered in these trials. Duration of ginger supple-
mentation ranged from 8 weeks to 3 months. Among the
nine studies included in the meta-analysis, four articles
included patients with type 2 diabetes (8, 29, 32, 33), two
articles included patients undergoing peritoneal dialysis
(PD) (15, 31), one article included obese patients (BMI ]
30 kg/m2) (30), one article included patients with BMI
2529.9 kg/m2 (28), and one article included patients
with hyperlipidaemia (34). Ginger appeared safe and well-
tolerated in all RCTs included in this analysis, with
no reports of any serious adverse events. Demographic
and baseline parameters of the included studies are shown
in Table 1.
Pooled estimate of the effect of ginger administration on
CRP
The pooled estimate (WMD) of the effect of ginger
administration on CRP levels was 0.84 mg/L (95%
CI1.38 to 0.31, heterogeneity p0.053) across all
studies (Fig. 2). The pooled estimate (WMD) of the effect
of ginger administration on fasting blood glucose (FBG)
levels was 1.35 mg/dl (95% CI2.04 to 0.58, hetero-
geneity p0.056) across all studies. Pooled estimate of the
effect of ginger on lipid profile and HbA1c is reported in
Table 2.
Sensitivity analysis
In leave-one-out sensitivity analyses, the pooled effect
estimates remained similar for both CRP and FBG:0.84
mg/l (95% CI 1.38 to 0.31) and1.75 mg/dl (95%
CI 2.66 to 0.84), respectively. This result confirms
that the significant difference between the studied groups is
the overall effect of all included studies.
Meta-regression
Random-effects meta-regression was performed to
evaluate the impact of potential moderators on the
estimated effect size. Changes in plasma CRP levels
were independent of the dosage of ginger administration
(slope 0.20; 95% CI 0.95 to 0.55; p0.60; Fig. 3).
Publication bias
Visual inspection of funnel plot symmetry suggested no
potential publication bias for the comparison of plasma
CRP levels between ginger-administrated groups and
placebo groups (Fig. 4). Moreover, the Egger’s linear
regression (intercept4.25, standard error1.7; 95%
CI 9.6 to 1.1, t2.48, df3.00, two-tailed p0.088)
and Begg’s rank correlation test (Kendall’s t with con-
tinuity correction0.600, z1.46, two-tailed p0.14)
were not indicative for publication bias. After adjustment
of effect size for potential publication bias using the
‘trim and fill’ correction, no potentially missing study
was imputed in the funnel plot (WMD 0.84 mg/L, 95%
CI 1.38 to 0.31; Fig. 5). The ‘fail-safe N’ test showed
that 120 studies would be needed to bring the WMD down
to a non-significant (p0.05) value.
Discussion
This meta-analysis suggests that ginger administration
significantly reduced CRP level and improved glycaemia
index and lipid profile. In agreement with our findings,
some of the included studies have reported that ginger
(Z. officinale) reduces inflammatory markers (8, 32).
Arablou et al. indicated that consumption of ginger
powder for 12 weeks can reduce CRP significantly in
patients with type 2 diabetes (8). Their findings are in line
with the result of Atashak et al. (31), which showed that
consumption of 1 g of powdered ginger daily for 10 weeks
led to a 27.6% reduction in mean CRP levels in obese men.
Imani et al. have reported that daily administration of
1,000 mg ginger had no effect on serum CRP in patients
on PD and stated that the reason for this disparity may be
due to the administration of a higher dose of ginger in the
other studies (15).
It should be noted that there are contradictory findings
about the effects of ginger supplementation on inflamma-
tory marker between studies, which are not included in this
meta-analysis. Naderi et al. conducted a 12-week clinical
trial to investigate the effects of ginger supplementation on
nitric oxide and CRP in elderly knee osteoarthritis patients
Mohsen Mazidi et al.
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Table 1. General characteristics of nine studies eligible for inclusion in meta-analysis
First author,
reference # Country Study design Inclusion criteria
Treatment
duration
Sample
size Age (years)
Female
(n,%)
Ginger
dose
Arablou T.
2014 (8)
Iran Double-blinded,
placebo-controlled
clinical trial
Patients 3070 years old
with type 2 diabetes
12 weeks 63 Ginger group
(52.698.4)
Placebo group
(52.099.0)
Ginger group
(75.8%)
Placebo group
(76.7%)
1,600
mg/day
Atashak S.
2010 (30)
Iran Randomized double-
blind, placebo-
controlled trial
Obese men (BMI ]30
kg/m2, aged 1830 years)
10 weeks 32 Ginger group (23.7)
Placebo group
(25.4)
(0%) 1 g/day
Imani H.
2015 (15)
Iran Randomized, double-
blind, placebo-
controlled trial
Patients undergoing
continuous ambulatory
peritoneal dialysis in the
age range of 2979 years
10 weeks 36 Ginger group
(5692.5)
Placebo group
(5893)
Ginger group
(39%)
Placebo group
(44%)
1,000
mg/day
Mansour M.
2012 (28)
USA Randomized
crossover study
Men, age 1950 years,
BMI 2529.9 kg/m2
Not
mentioned
10 39.193.3 0 2 g/day
Shidfar F.
2015 (33)
Iran Double-blind,
placebo-controlled,
randomized clinical
trial
20- to 60-year-old
patients with type 2
diabetes who did not
receive insulin
3 months 45 Ginger group
(45.297.64)
Placebo group
(47.198.31)
Fill in 3 g/day
Alizadeh-
Navaei R.
2008 (34)
Iran Double-blind
controlled clinical
trial study
Patients with
hyperlipidaemia
45 days 85 Ginger group
(53.8911.8)
Placebo group
(53.5911)
Ginger group
(64.4%)
Placebo group
(55%)
3 g/day
Mahluji S.
2013 (32)
Iran Randomized, double-
blind, placebo-
controlled trial
Patients with type 2
diabetes
2 months 54 Ginger group
(49.295.1)
Placebo group
(53.197.9)
Ginger group
(46%)
Placebo group
(42%)
2 g/day
Mozaffari-
Khosravi
H. 2014
(29)
Iran Randomized, double-
blind, placebo-
controlled trial
Type 2 diabetes 2 months 88 Ginger group
(49.8397.23)
Placebo group
(51.0597.70)
Ginger group
(56.1%)
Placebo group
(67.5%)
3 g/day
Tabibi H.
2016 (31)
Iran Randomized, double-
blind, placebo-
controlled trial
Peritoneal dialysis 10 weeks 36 Ginger group
(56.092.5)
Placebo group
(58.093.0)
Ginger group
(39%)
Placebo group
(44%)
1 g/day
–1.661
–0.695
–1.046
–0.261
–0.320
–1.576
0.580
0.156
0.318
0.335
0.254
0.512
0.336
0.024
0.101
0.112
0.064
0.262
–2.798
–1.001
–1.669
–0.918
–0.817
–2.579
–0.525
–0.390
–0.423
0.395
0.178
–0.573
–2.865
–4.460
–3.290
–0.781
–1.260
–3.079
0.004
Ginger supplemented
group
Placebo group
0.001
0.000
0.435
0.208
0.002
Shidfar F,2015
lmani H,2015
Arablou T,2014
Mansour M,2012
Atashak S,2011
Study name Statistics for each study Std diff in means and 95% CI
Std diff
in means
Standard
error p-Value
–4.00 –2.00 0.00 4.002.00
Z-Value
Upper
limit
Lower
limitVariance
Fig. 2. The pooled estimate (weighted mean difference) of the effect of ginger administration on CRP levels.
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and reported that ginger powder supplementation at a
dose of 1 g/d can reduce inflammatory markers in patients
with knee osteoarthritis (5), which is in line with the
findings of a study by Rahimlou et al. (35). However, one
study reported that after oral administration of 1001,000
mg/ml squeezed ginger extract in mice, the production of
inflammatory markers increased (16).
Chronic inflammation and activation of the innate
immune system are strongly involved in the pathogenesis
of diabetes (8, 36). In addition, it has been stated that the
inflammatory marker CRP in adults has value for treat-
ment initiation in individuals with intermediate CVD risk
(38). Regarding the mechanism of the effect of ginger
on PGE2, an inhibition of cyclooxygenase-2 mRNA
expression and direct inhibition of this enzyme activity is
proposed (8, 38). Furthermore, it has been reported that
the effect of ginger on inflammation is also due to the effect
of certain active compounds (gingerols and zerumbone)
that inhibit NF-kB and TNF-a expression in liver cancer
cells (1). 6-Gingerol and 6-paradol have strong and
effective anti-inflammatory activity and suppress TNF-a
production (8, 39). This inhibition decreases NF-kB
activity in addition to other inflammatory cytokines as
well as cyclooxygenase 2 and its associated products
including PGE2. Therefore, acute-phase proteins such as
CRP are also inhibited in this process.
Moreover, other possible mechanisms are proposed
regarding pharmacological activity of ginger. Ginger
suppresses LT biosynthesis by inhibiting 5-lipoxygenase
(6, 40) l, and ginger extract was found to inhibit b-amyloid
peptide-induced cytokine and chemokine expression in a
cell line of human monocytes (6, 41).
Several papers have proposed that the hypoglycaemic
and other pharmacological activities of ginger are due
to its content of phenols, polyphenols, and flavonoids (42).
In vitro studies on the mechanism of the effect of ginger
on glucose metabolism have shown that the active con-
stituents of ginger including 6-gingerol and 8-gingerol
enhanced cellular glucose uptake by increasing gene
expression of glucose transporter type 4 (43, 44). Another
proposed mechanism is that ginger decreases blood
glucose by antagonistic activity against serotonin recep-
tors (8, 45). Moreover, several studies have reported
that ginger supplementation can affect glucose transport
and tolerance in type 2 diabetic patients with insulin
resistance. Isa et al. indicated that the 6-gingerol and
6-shogaol in ginger upregulate adiponectin, and 6-shogaol
has agonistic activity with PPARg. Thus, increasing
adiponectin improves insulin sensitivity (46, 47).
Table 2. The pooled estimate (weighted mean difference) of the
effect of ginger administration on glycaemia and lipid profile
Variables Result of meta-analysis
Low-density lipoprotein 1.33 mg/dl (95% CI 2.54 to 0.11)
High-density lipoprotein 1.16 mg/dl (95% CI 0.52 to 1.08)
Total cholesterol 0.22 mg/dl (95% CI 0.06 to 0.48)
Triglyceride 1.63 mg/dl (95% CI 3.10 to 0.17)
HbA1c 1.01% (95% CI 1.28 to 0.72)
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Fig. 3. Regression of standardized mean difference on dose. Meta-regression plots of the association between mean changes in
C-reactive protein (CRP) after ginger supplementation with dose of treatment. Circles represent each study, middle line is
regression line, and two lines around the middle line represent the 95% confidence interval.
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We acknowledge several limitations in our review
and meta-analysis. First, as with any meta-analysis,
internal validity relies on the quality of individual studies.
Several limitations can be named in this regard. Most of
the included studies had relatively medium sample sizes,
potentially leading to overestimation of treatment effects;
smaller trials might be methodologically less robust
and more prone to report larger effect sizes (48, 49).
The number of available studies concerning the described
topic was rather small. Moreover, most of the studies
were conducted in clinical populations rather than in
generally healthy populations, and this is likely to
affect the baseline levels of CRP and the inflammatory
markers.
Conclusion
This systematic review showed that ginger supplementation
can improve CRP level, glycaemia indexes, and lipid profile,
which can be useful for the prevention and management of
CVD. RCTs with a larger sample size and a longer follow-
up period should be considered for future investigations to
give an unequivocal answer as to whether ginger can reduce
CRP and improve glycaemia indexes and lipid profile.
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